CTRI/2024/01/061359尚未招募Unknown
Anemia Management in Chronic Kidney Disease: AComparative Evaluation of HIF-PHD Inhibitor(s) and ESAs - NI
ational Institute of Pharmaceutical Education and Research, Mohali0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •A.All patients who are diagnosed with CKD with renal anemia & undergoing dialysis
- •B.Patient should have been on dialysis for at least 3 months.
- •C.Patients between 18-75 years will receive HIF-PHD inhibitors or ESAs
排除标准
- •A.Inability to give informed consent
- •B.Patients unable to complete the interview
- •C.Psychiatric illness
- •D.History of malignancy
- •E.Any active or recent history of blood loss
- •F.Taking part in other drug studies
- •G.Pregnant and breastfeeding women
研究者
相似试验
招募中
4 期
This research aims to understand better treatment approaches for managing anemia in patients with CKD, with the ultimate goal of significantly enhancing patient care and overall treatment outcomes.CTRI/2024/05/066877ational Institute of Pharmaceutical Education and Research, Mohali
已完成
不适用
Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid TrialChronic Kidney DiseaseEnd Stage Renal DiseaseNCT01992926Vanderbilt University109
已完成
不适用
Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal PatientsFunctional Iron DeficiencyEnd-Stage Renal FailureNCT01126905University of Ulster250
已完成
不适用
Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group RecommendationsANEMIANCT01903148Fundación Senefro455
撤回
2 期
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and AnemiaChronic Kidney DiseaseAnemiaNCT00609544Regeneron Pharmaceuticals